Skip to main content
Erschienen in: Diabetologia 6/2015

01.06.2015 | Article

Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum

verfasst von: Caroline K. Kramer, Chang Ye, Anthony J. G. Hanley, Philip W. Connelly, Mathew Sermer, Bernard Zinman, Ravi Retnakaran

Erschienen in: Diabetologia | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

On cross-sectional assessment, a delayed timing of the peak blood glucose level at ≥60 min post-challenge on an OGTT is associated with beta cell dysfunction. In this context, we hypothesised that longitudinal changes in the timing of this peak might predict changes in glucose metabolism. We thus sought to evaluate the longitudinal associations of changes in the timing of the peak glucose level with changes over time in insulin sensitivity, beta cell function and glucose tolerance.

Methods

A total of 532 women underwent an OGTT at both 3 months and 12 months postpartum. The participants were stratified into four groups according to the change in timing of their glucose peak between the two visits: women with no change in timing of the glucose peak at 30 min (n = 217), those whose glucose peak shifted to an earlier time point (n = 120), those whose peak shifted to a later time point (n = 87) and women with an unchanged glucose peak at ≥60 min (n = 108). Beta cell function was measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2).

Results

Compared with an unchanged glucose peak at 30 min, both the shift of the glucose peak to a later time point and a peak that was unchanged at ≥60 min were independently associated with declining ISSI-2 scores (β = −127.5, p < 0.001 and β = −98.8, p = 0.006, respectively) and increased 2 h post-challenge glucose levels (β = 1.28, p < 0.001 and β = 0.91, p < 0.001, respectively) between the two visits. Furthermore, both these patterns of change in peak were independently associated with worsening glucose tolerance (from normal to prediabetes [defined as impaired fasting glucose or impaired glucose tolerance]/diabetes or from prediabetes to diabetes) (OR 8.1, 95% CI 3.0, 22.1 and OR 3.7, 95% CI 1.2, 11.7, respectively).

Conclusions/interpretation

A delayed timing of the post-challenge peak glucose level is associated with declining beta cell function and worsening glucose tolerance over time.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Standards of medical care in diabetes—2014 (2014) Diabetes Care 37(Suppl 1):S14–S80 Standards of medical care in diabetes—2014 (2014) Diabetes Care 37(Suppl 1):S14–S80
2.
Zurück zum Zitat Barrett-Connor E (2002) The oral glucose tolerance test, revisited. Eur Heart J 23:1229–1231CrossRefPubMed Barrett-Connor E (2002) The oral glucose tolerance test, revisited. Eur Heart J 23:1229–1231CrossRefPubMed
3.
Zurück zum Zitat Kim JY, Coletta DK, Mandarino LJ, Shaibi GQ (2012) Glucose response curve and type 2 diabetes risk in Latino adolescents. Diabetes Care 35:1925–1930CrossRefPubMedCentralPubMed Kim JY, Coletta DK, Mandarino LJ, Shaibi GQ (2012) Glucose response curve and type 2 diabetes risk in Latino adolescents. Diabetes Care 35:1925–1930CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Nolfe G, Spreghini MR, Sforza RW, Morino G, Manco M (2012) Beyond the morphology of the glucose curve following an oral glucose tolerance test in obese youth. Eur J Endocrinol 166:107–114CrossRefPubMed Nolfe G, Spreghini MR, Sforza RW, Morino G, Manco M (2012) Beyond the morphology of the glucose curve following an oral glucose tolerance test in obese youth. Eur J Endocrinol 166:107–114CrossRefPubMed
5.
Zurück zum Zitat Tschritter O, Fritsche A, Shirkavand F, Machicao F, Haring H, Stumvoll M (2003) Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 26:1026–1033CrossRefPubMed Tschritter O, Fritsche A, Shirkavand F, Machicao F, Haring H, Stumvoll M (2003) Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 26:1026–1033CrossRefPubMed
6.
Zurück zum Zitat Hayashi T, Boyko EJ, Sato KK et al (2013) Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans. Diabetes Care 36:1229–1235CrossRefPubMedCentralPubMed Hayashi T, Boyko EJ, Sato KK et al (2013) Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans. Diabetes Care 36:1229–1235CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B (2010) Risk of early progression to prediabetes or diabetes in women with recent gestational dysglycaemia but normal glucose tolerance at 3-month postpartum. Clin Endocrinol 73:476–483 Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B (2010) Risk of early progression to prediabetes or diabetes in women with recent gestational dysglycaemia but normal glucose tolerance at 3-month postpartum. Clin Endocrinol 73:476–483
8.
Zurück zum Zitat Alyass A, Almgren P, Akerlund M et al (2015) Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 58:87–97CrossRefPubMed Alyass A, Almgren P, Akerlund M et al (2015) Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 58:87–97CrossRefPubMed
9.
Zurück zum Zitat Abdul-Ghani MA, Williams K, DeFronzo R, Stern M (2006) Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29:1613–1618CrossRefPubMed Abdul-Ghani MA, Williams K, DeFronzo R, Stern M (2006) Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29:1613–1618CrossRefPubMed
10.
Zurück zum Zitat Kramer CK, Vuksan V, Choi H, Zinman B, Retnakaran R (2014) Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Res Clin Pract 105:88–95CrossRefPubMed Kramer CK, Vuksan V, Choi H, Zinman B, Retnakaran R (2014) Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Res Clin Pract 105:88–95CrossRefPubMed
11.
Zurück zum Zitat Kramer CK, Swaminathan B, Hanley AJ et al (2014) Prospective associations of vitamin D status with beta-cell function, insulin sensitivity and glycemia: the impact of parathyroid hormone status. Diabetes 63:3868–3879CrossRefPubMed Kramer CK, Swaminathan B, Hanley AJ et al (2014) Prospective associations of vitamin D status with beta-cell function, insulin sensitivity and glycemia: the impact of parathyroid hormone status. Diabetes 63:3868–3879CrossRefPubMed
12.
Zurück zum Zitat Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B (2008) Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care 31:2026–2031CrossRefPubMedCentralPubMed Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B (2008) Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care 31:2026–2031CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013) Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 37(Suppl 1):S8–S11 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013) Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 37(Suppl 1):S8–S11
14.
Zurück zum Zitat Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
15.
Zurück zum Zitat Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907CrossRefPubMed Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907CrossRefPubMed
16.
Zurück zum Zitat Retnakaran R, Qi Y, Goran MI, Hamilton JK (2009) Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 26:1198–1203CrossRefPubMed Retnakaran R, Qi Y, Goran MI, Hamilton JK (2009) Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 26:1198–1203CrossRefPubMed
17.
Zurück zum Zitat Zinman B, Harris SB, Neuman J et al (2010) Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376:103–111CrossRefPubMed Zinman B, Harris SB, Neuman J et al (2010) Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376:103–111CrossRefPubMed
18.
Zurück zum Zitat Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B (2014) Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA Trial. Diabetes Care 37:3270–3278CrossRefPubMed Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B (2014) Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA Trial. Diabetes Care 37:3270–3278CrossRefPubMed
19.
Zurück zum Zitat Kayaniyil S, Retnakaran R, Harris SB et al (2011) Prospective associations of vitamin D with beta-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes 60:2947–2953CrossRefPubMedCentralPubMed Kayaniyil S, Retnakaran R, Harris SB et al (2011) Prospective associations of vitamin D with beta-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes 60:2947–2953CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B (2010) Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 33:1798–1804CrossRefPubMedCentralPubMed Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B (2010) Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 33:1798–1804CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Kramer CK, Swaminathan B, Hanley AJ et al (2014) Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care 37:3262–3269CrossRefPubMed Kramer CK, Swaminathan B, Hanley AJ et al (2014) Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care 37:3262–3269CrossRefPubMed
22.
Zurück zum Zitat Kanauchi M, Kimura K, Kanauchi K, Saito Y (2005) Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 59:427–432CrossRefPubMed Kanauchi M, Kimura K, Kanauchi K, Saito Y (2005) Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 59:427–432CrossRefPubMed
23.
Zurück zum Zitat Zhou W, Gu Y, Li H, Luo M (2006) Assessing 1-h plasma glucose and shape of the glucose curve during oral glucose tolerance test. Eur J Endocrinol 155:191–197CrossRefPubMed Zhou W, Gu Y, Li H, Luo M (2006) Assessing 1-h plasma glucose and shape of the glucose curve during oral glucose tolerance test. Eur J Endocrinol 155:191–197CrossRefPubMed
24.
Zurück zum Zitat Abdul-Ghani MA, Lyssenko V, Tuomi T, Defronzo RA, Groop L (2010) The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 26:280–286CrossRefPubMed Abdul-Ghani MA, Lyssenko V, Tuomi T, Defronzo RA, Groop L (2010) The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 26:280–286CrossRefPubMed
25.
Zurück zum Zitat Tura A, Morbiducci U, Sbrignadello S, Winhofer Y, Pacini G, Kautzky-Willer A (2011) Shape of glucose, insulin, C-peptide curves during a 3-h oral glucose tolerance test: any relationship with the degree of glucose tolerance? Am J Physiol Regul Integr Comp Physiol 300:R941–R948CrossRefPubMed Tura A, Morbiducci U, Sbrignadello S, Winhofer Y, Pacini G, Kautzky-Willer A (2011) Shape of glucose, insulin, C-peptide curves during a 3-h oral glucose tolerance test: any relationship with the degree of glucose tolerance? Am J Physiol Regul Integr Comp Physiol 300:R941–R948CrossRefPubMed
26.
Zurück zum Zitat Frøslie KF, Røislien J, Qvigstad E et al (2013) Shape information from glucose curves: functional data analysis compared with traditional summary measures. BMC Med Res Methodol 13:6CrossRefPubMedCentralPubMed Frøslie KF, Røislien J, Qvigstad E et al (2013) Shape information from glucose curves: functional data analysis compared with traditional summary measures. BMC Med Res Methodol 13:6CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Frøslie KF, Røislien J, Qvigstad E et al (2014) Shape information in repeated glucose curves during pregnancy provided significant physiological information for neonatal outcomes. PLoS One 9:e90798CrossRefPubMedCentralPubMed Frøslie KF, Røislien J, Qvigstad E et al (2014) Shape information in repeated glucose curves during pregnancy provided significant physiological information for neonatal outcomes. PLoS One 9:e90798CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Ferrannini E, Natali A, Muscelli E et al (2011) Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 54:1507–1516CrossRefPubMed Ferrannini E, Natali A, Muscelli E et al (2011) Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 54:1507–1516CrossRefPubMed
29.
Zurück zum Zitat Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29CrossRefPubMed Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29CrossRefPubMed
30.
Zurück zum Zitat Caumo A, Luzi L (2004) First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 287:E371–E385CrossRefPubMed Caumo A, Luzi L (2004) First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 287:E371–E385CrossRefPubMed
31.
Zurück zum Zitat Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157CrossRefPubMed Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157CrossRefPubMed
32.
Zurück zum Zitat Woerle HJ, Carneiro L, Derani A, Goke B, Schirra J (2012) The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 61:2349–2358CrossRefPubMedCentralPubMed Woerle HJ, Carneiro L, Derani A, Goke B, Schirra J (2012) The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 61:2349–2358CrossRefPubMedCentralPubMed
Metadaten
Titel
Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum
verfasst von
Caroline K. Kramer
Chang Ye
Anthony J. G. Hanley
Philip W. Connelly
Mathew Sermer
Bernard Zinman
Ravi Retnakaran
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 6/2015
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3551-6

Weitere Artikel der Ausgabe 6/2015

Diabetologia 6/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.